↓ Skip to main content

Dove Medical Press

Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA

Overview of attention for article published in OncoTargets and therapy, December 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

patent
1 patent

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
40 Mendeley
Title
Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA
Published in
OncoTargets and therapy, December 2017
DOI 10.2147/ott.s144960
Pubmed ID
Authors

Marco D DiBonaventura, William Wong, Bijal Shah-Manek, Mathias Schulz

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 40 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 18%
Student > Ph. D. Student 6 15%
Other 4 10%
Student > Master 4 10%
Researcher 3 8%
Other 4 10%
Unknown 12 30%
Readers by discipline Count As %
Medicine and Dentistry 11 28%
Social Sciences 7 18%
Biochemistry, Genetics and Molecular Biology 2 5%
Immunology and Microbiology 1 3%
Psychology 1 3%
Other 5 13%
Unknown 13 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 December 2020.
All research outputs
#8,738,892
of 25,870,940 outputs
Outputs from OncoTargets and therapy
#564
of 3,017 outputs
Outputs of similar age
#158,353
of 448,465 outputs
Outputs of similar age from OncoTargets and therapy
#10
of 73 outputs
Altmetric has tracked 25,870,940 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,017 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 448,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.